Clinical Trials Browser

Has results × Lymphoma × Brentuximab Vedotin × Clear all

Hodgkin Disease, Lymphoma

NCT02588651 2025-11-21

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT01909934 2025-09-19

Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Phase 4 Completed

50 enrolled 22 charts

Lymphoid

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT03264131 2025-02-10

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

Phase 2 Active not recruiting

16 enrolled 8 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphatic Diseases, Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02388490 2024-09-23

Bretuximab

Phase 2 Completed

25 enrolled 12 charts

Lymphoid

Lymphoma, Recurrence

NCT01716806 2024-06-11

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Phase 2 Completed

131 enrolled 28 charts

Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Peripheral

NCT01492088 2024-05-30

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Phase 1/2 Completed

36 enrolled 26 charts

Lymphoid

Hodgkin Disease, Lymphoma, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT01777152 2021-11-30

ECHELON-2

Phase 3 Completed

452 enrolled 16 charts 2 FDA

Lymphoid

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT01100502 2021-05-14

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Phase 3 Completed

329 enrolled 15 charts

Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma

NCT01990534 2021-04-09

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Phase 4 Completed

60 enrolled 21 charts

Lymphoid

Hematologic Diseases, Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02169505 2019-11-27

Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)

Phase 2 Terminated

2 enrolled 5 charts

Lymphoid

Graft vs Host Disease, Hodgkin Disease, Lymphoma, Lymphoma, Large-Cell, Anaplastic

NCT01874054 2019-02-12

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

Phase 1/2 Completed

55 enrolled 14 charts

Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma

NCT00866047 2017-03-22

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma

Phase 2 Completed

58 enrolled 19 charts

Lymphoid

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic

NCT00848926 2017-03-13

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

Phase 2 Completed

102 enrolled 19 charts

Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma

NCT01421667 2016-11-28

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 2 Completed

176 enrolled 30 charts

Lymphoid

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01950364 2016-05-11

A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

Phase 1 Completed

20 enrolled 59 charts

Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT00365274 2014-06-02

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

Phase 2 Terminated

6 enrolled 3 charts

Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Clinical Trials

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

Bretuximab

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

ECHELON-2

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma